Healthcare Realty Trust Reports Results for the Fourth Quarter and Announces Quarterly Dividend
Healthcare Realty Trust (NYSE:HR) reported Q4 2024 results with a net loss of $(106.8) million, or $(0.31) per diluted share. Key highlights include:
- Normalized FFO per share of $0.40 for Q4, up 2.5% year-over-year, and $1.56 for full-year 2024
- Same-store cash NOI growth of 3.1% in Q4 and 2.9% for 2024
- Multi-tenant absorption of 140,000 square feet in Q4
- Record new lease signings of 686,000 square feet in Q4
The company generated $1.3 billion in proceeds for the year through:
- $770 million from joint venture transactions
- $491 million from asset sales
- Repurchased 31 million shares totaling $510 million at $16.56 per share average
The company declared a quarterly dividend of $0.31 per share and provided 2025 Normalized FFO guidance of $1.56-$1.60 per share.
Healthcare Realty Trust (NYSE:HR) ha riportato i risultati del Q4 2024 con una perdita netta di $(106.8) milioni, ovvero $(0.31) per azione diluita. I punti salienti includono:
- FFO normalizzato per azione di $0.40 per il Q4, in aumento del 2.5% rispetto all'anno precedente, e $1.56 per l'intero anno 2024
- Crescita del NOI in contante per negozi comparabili del 3.1% nel Q4 e del 2.9% per il 2024
- Assorbimento multi-inquilino di 140.000 piedi quadrati nel Q4
- Record di nuove firme di contratti di locazione per 686.000 piedi quadrati nel Q4
La società ha generato $1.3 miliardi di ricavi per l'anno tramite:
- $770 milioni da transazioni di joint venture
- $491 milioni da vendite di beni
- Riacquisto di 31 milioni di azioni per un totale di $510 milioni a una media di $16.56 per azione
La società ha dichiarato un dividendo trimestrale di $0.31 per azione e ha fornito una guida per il 2025 sul FFO normalizzato di $1.56-$1.60 per azione.
Healthcare Realty Trust (NYSE:HR) reportó resultados del Q4 2024 con una pérdida neta de $(106.8) millones, o $(0.31) por acción diluida. Los aspectos destacados incluyen:
- FFO normalizado por acción de $0.40 para el Q4, un aumento del 2.5% interanual, y $1.56 para el año completo 2024
- Crecimiento del NOI en efectivo de tiendas comparables del 3.1% en el Q4 y del 2.9% para el 2024
- Absorción multi-inquilino de 140,000 pies cuadrados en el Q4
- Registro de nuevas firmas de arrendamiento de 686,000 pies cuadrados en el Q4
La compañía generó $1.3 mil millones en ingresos para el año a través de:
- $770 millones de transacciones de joint venture
- $491 millones de ventas de activos
- Recompra de 31 millones de acciones por un total de $510 millones a un promedio de $16.56 por acción
La compañía declaró un dividendo trimestral de $0.31 por acción y proporcionó una guía de FFO normalizado de $1.56-$1.60 por acción para 2025.
Healthcare Realty Trust (NYSE:HR)는 2024년 4분기 결과로 $(106.8) 백만의 순손실을 보고했으며, 희석주당 $(0.31)입니다. 주요 하이라이트는 다음과 같습니다:
- 4분기 주당 정규화된 FFO는 $0.40로, 전년 대비 2.5% 증가하였고, 2024년 전체 연간으로는 $1.56입니다.
- 4분기 및 2024년 동안 같은 매장 현금 NOI 성장률은 각각 3.1% 및 2.9%입니다.
- 4분기 다세대 임대 공간 흡수는 140,000 평방피트입니다.
- 4분기 신규 임대 계약 체결 기록은 686,000 평방피트입니다.
회사는 다음을 통해 연간 $1.3억의 수익을 창출했습니다:
- 조인트 벤처 거래에서 $770백만
- 자산 판매에서 $491백만
- 주당 평균 $16.56로 총 $510백만에 3,100만 주를 재매입했습니다.
회사는 주당 $0.31의 분기 배당금을 선언했으며, 2025년 정규화된 FFO 가이던스를 주당 $1.56-$1.60으로 제공했습니다.
Healthcare Realty Trust (NYSE:HR) a rapporté des résultats pour le 4ème trimestre 2024 avec une perte nette de $(106.8) millions, soit $(0.31) par action diluée. Les points clés incluent :
- FFO normalisé par action de $0.40 pour le 4ème trimestre, en hausse de 2.5% par rapport à l'année précédente, et $1.56 pour l'année complète 2024
- Croissance du NOI en espèces des magasins comparables de 3.1% au 4ème trimestre et de 2.9% pour 2024
- Absorption multi-locataires de 140,000 pieds carrés au 4ème trimestre
- Record de nouvelles signatures de baux de 686,000 pieds carrés au 4ème trimestre
L'entreprise a généré $1.3 milliard de produits pour l'année grâce à :
- $770 millions provenant de transactions de coentreprise
- $491 millions provenant de ventes d'actifs
- Rachat de 31 millions d'actions pour un total de $510 millions à un prix moyen de $16.56 par action
L'entreprise a déclaré un dividende trimestriel de $0.31 par action et a fourni des prévisions de FFO normalisé de $1.56-$1.60 par action pour 2025.
Healthcare Realty Trust (NYSE:HR) hat die Ergebnisse für das 4. Quartal 2024 mit einem Nettoverlust von $(106.8) Millionen oder $(0.31) pro verwässerter Aktie gemeldet. Zu den wichtigsten Punkten gehören:
- Normalisiertes FFO pro Aktie von $0.40 für das 4. Quartal, ein Anstieg von 2.5% im Jahresvergleich, und $1.56 für das Gesamtjahr 2024
- Wachstum des Same-Store-Cash-NOI von 3.1% im 4. Quartal und 2.9% für 2024
- Multi-Tenant-Absorption von 140.000 Quadratfuß im 4. Quartal
- Rekordneue Mietverträge über 686.000 Quadratfuß im 4. Quartal
Das Unternehmen erzielte im Jahr Einnahmen in Höhe von $1.3 Milliarden durch:
- $770 Millionen aus Joint-Venture-Transaktionen
- $491 Millionen aus dem Verkauf von Vermögenswerten
- Rückkauf von 31 Millionen Aktien für insgesamt $510 Millionen zu einem Durchschnittspreis von $16.56 pro Aktie
Das Unternehmen erklärte eine vierteljährliche Dividende von $0.31 pro Aktie und gab eine Prognose für das Jahr 2025 für das normalisierte FFO von $1.56-$1.60 pro Aktie ab.
- Normalized FFO per share increased 2.5% YoY to $0.40 in Q4
- Record new lease signings of 686,000 square feet in Q4
- Strong same-store cash NOI growth of 3.1% in Q4
- Generated $1.3 billion in proceeds from asset sales and joint ventures
- Successfully re-leased 80% of former Steward Health space
- Net loss of $(106.8) million in Q4 2024
- Impairment charges of $81.1 million in Q4
- Prospect Medical bankruptcy affecting $2.9 million annual revenue
- Leverage ratio at 6.4x net debt to adjusted EBITDA
Insights
Healthcare Realty Trust's Q4 2024 results present a complex picture that requires careful analysis across multiple dimensions. The normalized FFO of $0.40 per share, while meeting guidance, masks significant underlying challenges and transformative actions.
The company's operational metrics show resilience, with same-store NOI growth of 3.1% and particularly strong multi-tenant absorption of 140,000 square feet. The achievement of 686,000 square feet of new lease signings - a company record - demonstrates robust demand for medical office space and effective leasing execution.
However, several critical factors warrant investor attention:
- The significant asset monetization of
$1.3 billion through joint ventures and sales represents a strategic pivot, with proceeds primarily directed toward share repurchases ($510 million ) and debt reduction - The resolution of Steward Health's bankruptcy impact shows progress, with 80% of affected space re-leased, though the recent Prospect Medical bankruptcy adds new uncertainty
- The reduction in leverage to 6.4x net debt to adjusted EBITDA from 6.7x demonstrates commitment to balance sheet improvement, though still above ideal levels for the sector
The 2025 guidance of $1.56-$1.60 normalized FFO per share suggests stable operations, but the projected same-store NOI growth of 3.00-3.75% (excluding troubled tenants) indicates cautious optimism about core portfolio performance.
The ongoing leadership transition, with an interim CEO and active search for permanent leadership, adds an element of strategic uncertainty during a critical period of portfolio optimization and operational enhancement. The board refreshment with four new directors brings needed expertise but may result in strategic shifts once permanent leadership is established.
The maintained quarterly dividend of
NASHVILLE, Tenn., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Healthcare Realty Trust Incorporated (NYSE:HR) today announced results for the fourth quarter ended December 31, 2024. Net (loss) income attributable to common stockholders for the three months ended December 31, 2024 was
| KEY FOURTH QUARTER AND ANNUAL HIGHLIGHTS |
- Normalized FFO per share totaled
$0.40 for the quarter, at the high end of the previously provided guidance range and up2.5% over the prior year period. Normalized FFO per share was$1.56 for the year ended December 31, 2024. - Cash NOI growth in the fourth quarter and year was as shown below (for more detail on the impact of Steward Health and Prospect Medical please see the related section herein):
| ACTUAL | ||||
| 4Q 2024 | 2024 | |||
| Same store | 3.1 | % | 2.9 | % |
| Same store excluding Steward Health and Prospect Medical | 3.6 | % | 3.1 | % |
- 140,000 square feet, or 44 basis points, of multi-tenant absorption for the quarter and 479,000 square feet, or 149 basis points, for the year
- 686,000 square feet of signed new leases in the quarter, the sixth consecutive quarter above 400,000 and a new single-quarter high
| CAPITAL ALLOCATION |
- The Company closed joint venture and asset sale transactions totaling
$522 million in the fourth quarter, and generated approximately$1.3 billion of proceeds for the year, which includes the following:$770 million from joint venture transactions$491 million from asset sales
- For the year, the Company repurchased approximately 31 million shares totaling
$510 million at an average price of$16.56 per share. - The Company repaid its
$350 million term loan maturing in 2025 and ended the year with leverage at 6.4 times net debt to adjusted EBITDA.
| MULTI-TENANT GROWTH AND ABSORPTION |
- Compared to prior year periods, multi-tenant cash NOI growth in the fourth quarter and year was:
| ACTUAL | ||||
| 4Q 2024 | 2024 | |||
| Multi-tenant | 3.4 | % | 3.0 | % |
| Multi-tenant excluding Steward Health & Prospect Medical | 3.9 | % | 3.2 | % |
- Multi-tenant occupancy gains at the high end of full year 2024 guidance were:
| ACTUAL | 2024 GUIDANCE | |||
| 4Q 2024 | 2024 | LOW | HIGH | |
| Absorption (SF) | 140,182 | 479,439 | 370,000 | 490,000 |
| Change in occupancy (bps) | + 44 | + 149 | + 100 | + 150 |
- At the end of the year, the multi-tenant portfolio occupancy rate was
86.3% and the leased percentage was88.3% .
| LEASING |
- Portfolio leasing activity that commenced in the fourth quarter totaled 1,534,000 square feet related to 349 leases:
- 954,000 square feet of renewals
- 580,000 square feet of new and expansion lease commencements
- In the fourth quarter, the Company signed new leases totaling 686,000 square feet, a new, single-quarter high for the Company.
| SAME STORE METRICS |
- Cash NOI for the fourth quarter increased
3.1% over the same quarter in the prior year, and2.9% for the year ended December 31, 2024. Adjusted for the impact of Steward Health and Prospect Medical, cash NOI growth would have been3.6% for the fourth quarter and3.1% for the year. - Tenant retention for the fourth quarter was
81.6% and83.4% for the year. - Operating expenses for the fourth quarter increased
2.7% over the same quarter in the prior year, and0.2% for the year ended December 31, 2024. - MOB cash leasing spreads were
2.7% for the quarter and3.4% for the year.
| BALANCE SHEET |
- At year end, net debt to adjusted EBITDA was 6.4 times, down from 6.7 times at the end of the third quarter.
- The Company fully repaid its
$350 million Unsecured Term Loan maturing in 2025. - At year end, the Company had no balance on its revolving credit facility, resulting in
$1.5 billion of availability. - In January 2025, the Company repaid
$35 million of its term loans maturing in 2026.
| LEADERSHIP / GOVERNANCE |
- Connie Moore appointed Interim President & Chief Executive Officer
- Austen Helfrich promoted to Chief Financial Officer
- Significant board refreshment in 2024, with four new directors joining, each with deep REIT industry and leadership experience
- Tom Bohjalian appointed Independent Chair of the Board
- Search committee of the board, chaired by Glenn Rufrano, conducting a search for a permanent President & Chief Executive Officer
| DIVIDEND |
- A common stock cash dividend in the amount of
$0.31 per share will be paid on March 19, 2025 to Class A common stockholders of record on March 3, 2025. Additionally, the eligible holders of operating partnership units will receive a distribution of$0.31 per unit, equivalent to the Company's Class A common stock dividend.
| STEWARD HEALTH AND PROSPECT MEDICAL UPDATE |
- During the fourth quarter, the Company made significant progress re-leasing space previously occupied by Steward Health, with leases in-place for over
80% of the previously occupied 593,000 square feet. Based on these actions, the Company entered 2025 having replaced approximately$19 million of the$27 million of pre-bankruptcy total exposure to Steward. Longer term, the Company continues to expect to recover over80% of the pre-bankruptcy Steward Health revenue. - On January 11, 2025, Prospect Medical filed for Chapter 11 bankruptcy protection. Prospect Medical leases approximately 81,000 square feet of space from the Company accounting for approximately
$2.9 million of annual revenue. 2025 guidance provided herein assumes no revenue collected from the Prospect leases.
| GUIDANCE |
- The Company's 2025 per share estimated guidance ranges are as follows:
| ACTUAL | 2025 GUIDANCE | |||||||||
| 2024 | LOW | HIGH | ||||||||
| Earnings per share | $ | (1.81 | ) | $ | (0.28 | ) | $ | (0.20 | ) | |
| NAREIT FFO per share | $ | 0.52 | $ | 1.44 | $ | 1.48 | ||||
| Normalized FFO per share | $ | 1.56 | $ | 1.56 | $ | 1.60 | ||||
- The Company's 2025 same store cash NOI growth estimated guidance range is
3.00% to3.75% , which excludes the impact of Prospect Medical and Steward Health. - The Company's 2025 guidance range includes activities outlined on page 29 of the Supplemental Information.
The 2025 annual guidance range reflects the Company's view of current and future market conditions, including assumptions with respect to rental rates, occupancy levels, interest rates, and operating and general and administrative expenses. The Company's guidance does not contemplate impacts from gains or losses from dispositions, potential impairments, or debt extinguishment costs, if any. There can be no assurance that the Company's actual results will not be materially higher or lower than these expectations. If actual results vary from these assumptions, the Company's expectations may change.
| EARNINGS CALL |
- On Wednesday, February 19, 2025, at 11:00 a.m. Eastern Time, Healthcare Realty Trust has scheduled a conference call to discuss earnings results, quarterly activities, general operations of the Company and industry trends.
- Simultaneously, a webcast of the conference call will be available to interested parties at https://investors.healthcarerealty.com/corporate-profile/webcasts under the Investor Relations section. A webcast replay will be available following the call at the same address.
- Live Conference Call Access Details:
- Domestic Dial-In Number: +1 646-968-2525 access code 4950066;
- All Other Locations: +1 888-596-4144 access code 4950066.
- Replay Information:
- Domestic Dial-In Number: +1 609-800-9909 access code 4950066;
- All Other Locations: +1 800-770-2030 access code 4950066.
Healthcare Realty (NYSE: HR) is a real estate investment trust (REIT) that owns and operates medical outpatient buildings primarily located around market-leading hospital campuses. The Company selectively grows its portfolio through property acquisition and development. As the first and largest REIT to specialize in medical outpatient buildings, Healthcare Realty's portfolio includes over 650 properties totaling more than 38 million square feet concentrated in 15 growth markets.
Additional information regarding the Company, including this quarter's operations, can be found at www.healthcarerealty.com. In addition to the historical information contained within, this press release contains certain forward-looking statements with respect to the Company. Forward-looking statements are statements that are not descriptions of historical facts and include statements regarding management’s intentions, beliefs, expectations, plans or predictions of the future, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Because such statements include risks, uncertainties and contingencies, actual results may differ materially and in adverse ways from those expressed or implied by such forward-looking statements. These risks, uncertainties and contingencies include, without limitation, the following: the Company's expected results may not be achieved; failure to realize the expected benefits of the Merger; significant transaction costs and/or unknown or inestimable liabilities; risks related to future opportunities and plans for the Company, including the uncertainty of expected future financial performance and results of the Company; the possibility that, if the Company does not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial analysts or investors, the market price of the Company’s common stock could decline; general adverse economic and local real estate conditions; changes in economic conditions generally and the real estate market specifically; legislative and regulatory changes, including changes to laws governing the taxation of REITs and changes to laws governing the healthcare industry; the availability of capital; changes in interest rates; competition in the real estate industry; the supply and demand for operating properties in the Company’s proposed market areas; changes in accounting principles generally accepted in the US; policies and guidelines applicable to REITs; the availability of properties to acquire; the availability of financing; pandemics and other health concerns, and the measures intended to prevent their spread and the potential material adverse effect these matters may have on the Company’s business, results of operations, cash flows and financial condition. Additional information concerning the Company and its business, including additional factors that could materially and adversely affect the Company’s financial results, include, without limitation, the risks described under Part I, Item 1A - Risk Factors, in the Company’s 2024 Annual Report on Form 10-K and in its other filings with the SEC.
| Consolidated Balance Sheets |
| DOLLARS IN THOUSANDS, EXCEPT PER SHARE DATA |
| ASSETS | |||||||||||||||
| 4Q 2024 | 3Q 2024 | 2Q 2024 | 1Q 2024 | 4Q 2023 | |||||||||||
| Real estate properties | |||||||||||||||
| Land | $ | 1,143,468 | $ | 1,195,116 | $ | 1,287,532 | $ | 1,342,895 | $ | 1,343,265 | |||||
| Buildings and improvements | 9,707,066 | 10,074,504 | 10,436,218 | 10,902,835 | 10,881,373 | ||||||||||
| Lease intangibles | 664,867 | 718,343 | 764,730 | 816,303 | 836,302 | ||||||||||
| Personal property | 9,909 | 9,246 | 12,501 | 12,720 | 12,718 | ||||||||||
| Investment in financing receivables, net | 123,671 | 123,045 | 122,413 | 122,001 | 122,602 | ||||||||||
| Financing lease right-of-use assets | 77,343 | 77,728 | 81,401 | 81,805 | 82,209 | ||||||||||
| Construction in progress | 31,978 | 125,944 | 97,732 | 70,651 | 60,727 | ||||||||||
| Land held for development | 52,408 | 52,408 | 59,871 | 59,871 | 59,871 | ||||||||||
| Total real estate investments | 11,810,710 | 12,376,334 | 12,862,398 | 13,409,081 | 13,399,067 | ||||||||||
| Less accumulated depreciation and amortization | (2,483,656 | ) | (2,478,544 | ) | (2,427,709 | ) | (2,374,047 | ) | (2,226,853 | ) | |||||
| Total real estate investments, net | 9,327,054 | 9,897,790 | 10,434,689 | 11,035,034 | 11,172,214 | ||||||||||
| Cash and cash equivalents 1 | 68,916 | 22,801 | 137,773 | 26,172 | 25,699 | ||||||||||
| Assets held for sale, net | 12,897 | 156,218 | 34,530 | 30,968 | 8,834 | ||||||||||
| Operating lease right-of-use assets | 261,438 | 259,013 | 261,976 | 273,949 | 275,975 | ||||||||||
| Investments in unconsolidated joint ventures | 473,122 | 417,084 | 374,841 | 309,754 | 311,511 | ||||||||||
| Other assets, net and goodwill | 507,496 | 491,679 | 559,818 | 605,047 | 842,898 | ||||||||||
| Total assets | $ | 10,650,923 | $ | 11,244,585 | $ | 11,803,627 | $ | 12,280,924 | $ | 12,637,131 | |||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||||||||
| 4Q 2024 | 3Q 2024 | 2Q 2024 | 1Q 2024 | 4Q 2023 | |||||||||||
| Liabilities | |||||||||||||||
| Notes and bonds payable | $ | 4,662,771 | $ | 4,957,796 | $ | 5,148,153 | $ | 5,108,279 | $ | 4,994,859 | |||||
| Accounts payable and accrued liabilities | 222,510 | 197,428 | 195,884 | 163,172 | 211,994 | ||||||||||
| Liabilities of properties held for sale | 1,283 | 7,919 | 1,805 | 700 | 295 | ||||||||||
| Operating lease liabilities | 224,499 | 229,925 | 230,601 | 229,223 | 229,714 | ||||||||||
| Financing lease liabilities | 72,346 | 71,887 | 75,199 | 74,769 | 74,503 | ||||||||||
| Other liabilities | 161,640 | 180,283 | 177,293 | 197,763 | 202,984 | ||||||||||
| Total liabilities | 5,345,049 | 5,645,238 | 5,828,935 | 5,773,906 | 5,714,349 | ||||||||||
| Redeemable non-controlling interests | 4,778 | 3,875 | 3,875 | 3,880 | 3,868 | ||||||||||
| Stockholders' equity | |||||||||||||||
| Preferred stock, | — | — | — | — | — | ||||||||||
| Common stock, | 3,505 | 3,558 | 3,643 | 3,815 | 3,810 | ||||||||||
| Additional paid-in capital | 9,118,229 | 9,198,004 | 9,340,028 | 9,609,530 | 9,602,592 | ||||||||||
| Accumulated other comprehensive (loss) income | (1,168 | ) | (16,963 | ) | 6,986 | 4,791 | (10,741 | ) | |||||||
| Cumulative net income attributable to common stockholders | 374,309 | 481,155 | 574,178 | 717,958 | 1,028,794 | ||||||||||
| Cumulative dividends | (4,260,014 | ) | (4,150,328 | ) | (4,037,693 | ) | (3,920,199 | ) | (3,801,793 | ) | |||||
| Total stockholders' equity | 5,234,861 | 5,515,426 | 5,887,142 | 6,415,895 | 6,822,662 | ||||||||||
| Non-controlling interest | 66,235 | 80,046 | 83,675 | 87,243 | 96,252 | ||||||||||
| Total Equity | 5,301,096 | 5,595,472 | 5,970,817 | 6,503,138 | 6,918,914 | ||||||||||
| Total liabilities and stockholders' equity | $ | 10,650,923 | $ | 11,244,585 | $ | 11,803,627 | $ | 12,280,924 | $ | 12,637,131 | |||||
- 2Q 2024 cash and cash equivalents includes
$96.0 million of proceeds held in a cash escrow account from a portfolio disposition that closed on June 28, 2024 and was received by the Company on July 1, 2024.
| Consolidated Statements of Income |
| DOLLARS IN THOUSANDS, EXCEPT PER SHARE DATA |
| THREE MONTHS ENDED DECEMBER 31, | TWELVE MONTHS ENDED DECEMBER 31, | |||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||
| Revenues | ||||||||||||
| Rental income 1 | $ | 300,065 | $ | 322,076 | $ | 1,232,776 | $ | 1,309,184 | ||||
| Interest income | 4,076 | 4,422 | 16,383 | 17,134 | ||||||||
| Other operating | 5,625 | 3,943 | 19,157 | 17,451 | ||||||||
| 309,766 | 330,441 | 1,268,316 | 1,343,769 | |||||||||
| Expenses | ||||||||||||
| Property operating | 114,415 | 121,362 | 473,444 | $ | 500,437 | |||||||
| General and administrative | 34,208 | 14,609 | 83,121 | $ | 58,405 | |||||||
| Normalizing items 2 | (22,991 | ) | (1,445 | ) | (29,852 | ) | (1,720 | ) | ||||
| Normalized general and administrative | 11,217 | 13,164 | 53,269 | 56,685 | ||||||||
| Transaction costs | 1,577 | 301 | 3,122 | 2,026 | ||||||||
| Merger-related costs | — | 1,414 | — | (1,952 | ) | |||||||
| Depreciation and amortization | 160,330 | 180,049 | 675,152 | 730,709 | ||||||||
| 310,530 | 317,735 | 1,234,839 | 1,289,625 | |||||||||
| Other income (expense) | ||||||||||||
| Interest expense before merger-related fair value | (47,951 | ) | (52,387 | ) | (201,758 | ) | (215,699 | ) | ||||
| Merger-related fair value adjustment | (10,314 | ) | (10,800 | ) | (40,667 | ) | (42,885 | ) | ||||
| Interest expense | (58,265 | ) | (63,187 | ) | (242,425 | ) | (258,584 | ) | ||||
| Gain on sales of real estate properties and other assets | 32,082 | 20,573 | 109,753 | 77,546 | ||||||||
| (Loss) gain on extinguishment of debt | (237 | ) | — | (237 | ) | 62 | ||||||
| Impairment of real estate assets and credit loss reserves | (81,098 | ) | (11,403 | ) | (313,547 | ) | (154,912 | ) | ||||
| Impairment of goodwill | — | — | (250,530 | ) | — | |||||||
| Equity income (loss) from unconsolidated joint ventures | 224 | (430 | ) | (135 | ) | (1,682 | ) | |||||
| Interest and other (expense) income, net | (154 | ) | 65 | (260 | ) | 1,343 | ||||||
| (107,448 | ) | (54,382 | ) | (697,381 | ) | (336,227 | ) | |||||
| Net (loss) income | $ | (108,212 | ) | $ | (41,676 | ) | $ | (663,904 | ) | $ | (282,083 | ) |
| Net loss (income) attributable to non-controlling interests | 1,366 | 1,143 | 9,419 | 3,822 | ||||||||
| Net (loss) income attributable to common stockholders | $ | (106,846 | ) | $ | (40,533 | ) | $ | (654,485 | ) | $ | (278,261 | ) |
| Basic earnings per common share | $ | (0.31 | ) | $ | (0.11 | ) | $ | (1.81 | ) | $ | (0.74 | ) |
| Diluted earnings per common share | $ | (0.31 | ) | $ | (0.11 | ) | $ | (1.81 | ) | $ | (0.74 | ) |
| Weighted average common shares outstanding - basic | 351,560 | 379,044 | 365,553 | 378,928 | ||||||||
| Weighted average common shares outstanding - diluted 3 | 351,560 | 379,044 | 365,553 | 378,928 | ||||||||
- In 4Q 2024, rental income was reduced by
$0.7 million for Prospect Medical revenue reserves. In 2Q 2024, rental income was reduced by$3.0 million for Steward Health revenue reserves. - Normalizing items primarily include restructuring, severance-related costs and non-routine advisory fees associated with shareholder engagement.
- Potential common shares are not included in the computation of diluted earnings per share when a loss exists, as the effect would be an antidilutive per share amount. As a result, the outstanding limited partnership units in the Company's operating partnership ("OP"), totaling 3,622,036 units were not included.
| Reconciliation of FFO, Normalized FFO and FAD 1,2,3 |
| DOLLARS IN THOUSANDS, EXCEPT PER SHARE DATA |
| THREE MONTHS ENDED DECEMBER 31, | TWELVE MONTHS ENDED DECEMBER 31, | |||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||
| Net loss attributable to common stockholders | $ | (106,846 | ) | $ | (40,533 | ) | $ | (654,485 | ) | $ | (278,261 | ) |
| Net loss attributable to common stockholders/diluted share 3 | $ | (0.31 | ) | $ | (0.11 | ) | $ | (1.81 | ) | $ | (0.74 | ) |
| Gain on sales of real estate assets | (32,082 | ) | (20,573 | ) | (104,684 | ) | (77,546 | ) | ||||
| Impairments of real estate assets | 75,423 | 11,403 | 249,909 | 149,717 | ||||||||
| Real estate depreciation and amortization | 164,656 | 182,272 | 690,988 | 738,526 | ||||||||
| Non-controlling loss from operating partnership units | (1,422 | ) | (491 | ) | (9,149 | ) | (3,426 | ) | ||||
| Unconsolidated JV depreciation and amortization | 5,913 | 4,442 | 20,678 | 18,116 | ||||||||
| FFO adjustments | $ | 212,488 | $ | 177,053 | $ | 847,742 | $ | 825,387 | ||||
| FFO adjustments per common share - diluted | $ | 0.60 | $ | 0.46 | $ | 2.29 | $ | 2.15 | ||||
| FFO | $ | 105,642 | $ | 136,520 | $ | 193,257 | $ | 547,126 | ||||
| FFO per common share - diluted 4 | $ | 0.30 | $ | 0.36 | $ | 0.52 | $ | 1.43 | ||||
| Transaction costs | 1,577 | 301 | 3,122 | 2,026 | ||||||||
| Merger-related costs | — | 1,414 | — | (1,952 | ) | |||||||
| Lease intangible amortization | (2,348 | ) | 261 | (2,054 | ) | 860 | ||||||
| Non-routine legal costs/forfeited earnest money received | 306 | (100 | ) | 1,077 | 175 | |||||||
| Debt financing costs | 237 | — | 237 | (62 | ) | |||||||
| Restructuring and severance-related charges | 22,991 | 1,445 | 29,852 | 1,445 | ||||||||
| Credit losses and gains (losses) on other assets, net 5 | 4,582 | — | 59,707 | 8,599 | ||||||||
| Impairment of goodwill | — | — | 250,530 | — | ||||||||
| Merger-related fair value adjustment | 10,314 | 10,800 | 40,667 | 42,885 | ||||||||
| Unconsolidated JV normalizing items 6 | 113 | 89 | 390 | 389 | ||||||||
| Normalized FFO adjustments | $ | 37,772 | $ | 14,210 | $ | 383,528 | $ | 54,365 | ||||
| Normalized FFO adjustments per common share - diluted | $ | 0.11 | $ | 0.04 | $ | 1.04 | $ | 0.14 | ||||
| Normalized FFO | $ | 143,414 | $ | 150,730 | $ | 576,785 | $ | 601,491 | ||||
| Normalized FFO per common share - diluted | $ | 0.40 | $ | 0.39 | $ | 1.56 | $ | 1.57 | ||||
| Non-real estate depreciation and amortization | 404 | 685 | 1,478 | 2,566 | ||||||||
| Non-cash interest amortization, net 7 | 1,239 | 1,265 | 5,101 | 4,968 | ||||||||
| Rent reserves, net 8 | (369 | ) | 1,404 | 714 | 3,163 | |||||||
| Straight-line rent income, net | (7,051 | ) | (7,872 | ) | (27,254 | ) | (32,592 | ) | ||||
| Stock-based compensation | 3,028 | 3,566 | 14,036 | 13,791 | ||||||||
| Unconsolidated JV non-cash items 9 | (277 | ) | (206 | ) | (923 | ) | (1,034 | ) | ||||
| Normalized FFO adjusted for non-cash items | 140,388 | 149,572 | 569,937 | 592,353 | ||||||||
| 2nd generation TI | (20,003 | ) | (18,715 | ) | (69,445 | ) | (66,081 | ) | ||||
| Leasing commissions paid | (11,957 | ) | (14,978 | ) | (47,450 | ) | (36,391 | ) | ||||
| Building capital | (8,347 | ) | (17,393 | ) | (33,934 | ) | (49,343 | ) | ||||
| Total maintenance capex | (40,307 | ) | (51,086 | ) | (150,829 | ) | (151,815 | ) | ||||
| FAD | $ | 100,081 | $ | 98,486 | $ | 419,108 | $ | 440,538 | ||||
| Quarterly/dividends and OP distributions | $ | 110,808 | $ | 118,897 | $ | 462,746 | 477,239 | |||||
| FFO wtd avg common shares outstanding - diluted 10 | 355,874 | 383,326 | 369,767 | 383,381 | ||||||||
- Funds from operations (“FFO”) and FFO per share are operating performance measures adopted by NAREIT. NAREIT defines FFO as “net income (computed in accordance with GAAP) excluding depreciation and amortization related to real estate, gains and losses from the sale of certain real estate assets, gains and losses from change in control, and impairment write-downs of certain real assets and investments in entities when the impairment is directly attributable to decreases in the value of depreciable real estate held by the entity.”
- FFO, Normalized FFO and Funds Available for Distribution ("FAD") do not represent cash generated from operating activities determined in accordance with GAAP and are not necessarily indicative of cash available to fund cash needs. FFO, Normalized FFO and FAD should not be considered alternatives to net income attributable to common stockholders as indicators of the Company's operating performance or as alternatives to cash flow as measures of liquidity.
- Potential common shares are not included in the computation of diluted earnings per share when a loss exists, as the effect would be an antidilutive per share amount.
- For 1Q 2024, basic weighted average common shares outstanding was the denominator used in the per share calculation.
- 4Q 2024 includes
$1.6 million of credit loss reserves, net of recoveries and a$4.1 million loss on other assets. These amounts were partially offset by a$1.1 million recovery of prior-period Steward Health straight-line rent for leases assumed. 3Q 2024 includes$46.8 million of credit loss reserves and$0.2 million gain on other assets. 2Q 2024 includes$11.2 million of credit loss reserves and$2.2 million write-off of prior period Steward Health straight-line rent, offset by$4.9 million gain on other assets. - Includes the Company's proportionate share of normalizing items related to unconsolidated joint ventures such as lease intangibles and acquisition and pursuit costs.
- Includes the amortization of deferred financing costs, discounts and premiums, and non-cash financing receivable amortization.
- 2Q 2024 includes
$0.8 million related to the Steward Health revenue reserve for March. - Includes the Company's proportionate share of straight-line rent, net and rent reserves, net related to unconsolidated joint ventures.
- The Company utilizes the treasury stock method, which includes the dilutive effect of nonvested share-based awards outstanding of 691,557 for the three months ended December 31, 2024. Also includes the diluted impact of 3,622,036 OP units outstanding.
| Reconciliation of Non-GAAP Measures |
| DOLLARS IN THOUSANDS, EXCEPT PER SHARE DATA - UNAUDITED |
Management considers funds from operations ("FFO"), FFO per share, normalized FFO, normalized FFO per share, and funds available for distribution ("FAD") to be useful non-GAAP measures of the Company's operating performance. A non-GAAP financial measure is generally defined as one that purports to measure historical financial performance, financial position or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable measure determined in accordance with GAAP. Set forth below are descriptions of the non-GAAP financial measures management considers relevant to the Company's business and useful to investors.
The non-GAAP financial measures presented herein are not necessarily identical to those presented by other real estate companies due to the fact that not all real estate companies use the same definitions. These measures should not be considered as alternatives to net income (determined in accordance with GAAP), as indicators of the Company's financial performance, or as alternatives to cash flow from operating activities (determined in accordance with GAAP) as measures of the Company's liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of the Company's needs.
FFO and FFO per share are operating performance measures adopted by the National Association of Real Estate Investment Trusts, Inc. (“NAREIT”). NAREIT defines FFO as “net income (computed in accordance with GAAP) excluding depreciation and amortization related to real estate, gains and losses from the sale of certain real estate assets, gains and losses from change in control, and impairment write-downs of certain real assets and investments in entities when the impairment is directly attributable to decreases in the value of depreciable real estate held by the entity.” The Company defines Normalized FFO as FFO excluding acquisition-related expenses, lease intangible amortization and other normalizing items that are unusual and infrequent in nature. FAD is presented by adding to Normalized FFO non-real estate depreciation and amortization, deferred financing fees amortization, share-based compensation expense and rent reserves, net; and subtracting maintenance capital expenditures, including second generation tenant improvements and leasing commissions paid and straight-line rent income, net of expense. The Company's definition of these terms may not be comparable to that of other real estate companies as they may have different methodologies for computing these amounts. FFO, Normalized FFO and FAD do not represent cash generated from operating activities determined in accordance with GAAP and are not necessarily indicative of cash available to fund cash needs. FFO, Normalized FFO and FAD should not be considered an alternative to net income as an indicator of the Company’s operating performance or as an alternative to cash flow as a measure of liquidity. FFO, Normalized FFO and FAD should be reviewed in connection with GAAP financial measures.
Management believes FFO, FFO per share, Normalized FFO, Normalized FFO per share, and FAD provide an understanding of the operating performance of the Company’s properties without giving effect to certain significant non-cash items, including depreciation and amortization expense. Historical cost accounting for real estate assets in accordance with GAAP assumes that the value of real estate assets diminishes predictably over time. However, real estate values instead have historically risen or fallen with market conditions. The Company believes that by excluding the effect of depreciation, amortization, gains or losses from sales of real estate, and other normalizing items that are unusual and infrequent, FFO, FFO per share, Normalized FFO, Normalized FFO per share and FAD can facilitate comparisons of operating performance between periods. The Company reports these measures because they have been observed by management to be the predominant measures used by the REIT industry and by industry analysts to evaluate REITs and because these measures are consistently reported, discussed, and compared by research analysts in their notes and publications about REITs.
Cash NOI and Same Store Cash NOI are key performance indicators. Management considers these to be supplemental measures that allow investors, analysts and Company management to measure unlevered property-level operating results. The Company defines Cash NOI as rental income and less property operating expenses. Cash NOI excludes non-cash items such as above and below market lease intangibles, straight-line rent, lease inducements, lease termination fees, tenant improvement amortization and leasing commission amortization. Cash NOI is historical and not necessarily indicative of future results.
Same Store Cash NOI compares Cash NOI for stabilized properties. Stabilized properties are properties that have been included in operations for the duration of the year-over-year comparison period presented. Accordingly, stabilized properties exclude properties that were recently acquired or disposed of, properties classified as held for sale, properties undergoing redevelopment, and newly redeveloped or developed properties.
The Company utilizes the redevelopment classification for properties where management has approved a change in strategic direction for such properties through the application of additional resources including an amount of capital expenditures significantly above routine maintenance and capital improvement expenditures.
Any recently acquired property will be included in the same store pool once the Company has owned the property for eight full quarters. Newly developed or redeveloped properties will be included in the same store pool eight full quarters after substantial completion.
Ron Hubbard
Vice President, Investor Relations
P: 615.269.8290
FAQ
What was Healthcare Realty Trust's (HR) Q4 2024 FFO per share?
How much did Healthcare Realty Trust (HR) spend on share buybacks in 2024?
What is Healthcare Realty Trust's (HR) dividend for Q4 2024?
What is Healthcare Realty Trust's (HR) 2025 FFO guidance?
What was Healthcare Realty Trust's (HR) same-store NOI growth in Q4 2024?
